Stuart Therapeutics has collected equity financing from investors including Wisconsin Alumni Research Foundation to fund phase 2 trials for a drug aimed at dry eye disease.

Stuart Therapeutics, a US-based biopharmaceutical company focused on ophthalmic diseases, completed an $11m series A round on Tuesday featuring Wisconsin Alumni Research Foundation, the tech transfer arm of University of Wisconsin-Madison.
InFocus Capital Partners led the round, which also featured Mimo Capital and Biobrit.
Founded in 2017, Stuart Therapeutics is working on treatments for a variety of diseases affecting the eye, such as glaucoma, dry and wet age-related macular degeneration and neurotrophic keratitis.
Its lead asset, ST-100,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in